ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center

ECOG-ACRIN 胸部恶性肿瘤综合转化科学中心

• 批准号: 9240603
• 负责人: Suresh S Ramalingam
• 金额: $ 77.27万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-06-19 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9240603
• 关键词: American College of Radiology Imaging Network; Area; Award; BRAF gene; Biological Markers; Cancer Patient; Center for Translational Science Activities; Chest; Clinical Data; Clinical Trials; Collaborations; Conduct Clinical Trials; DNA; Data; Development; Eastern Cooperative Oncology Group; Enrollment; Epidermal Growth Factor Receptor; Epigenetic Process; Evaluation; Future; Genes; Genetic; Genomics; Histologic; Individual; Institution; Lung Neoplasms; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of thorax; Methodology; Methods; Molecular; Molecular Abnormality; Molecular Analysis; Molecular Target; Mutation; Mutation Analysis; National Clinical Trials Network; Non-Small-Cell Lung Carcinoma; Oncogenic; Outcome; Patient Monitoring; Patient-Focused Outcomes; Patients; Pilot Projects; Plasma; Platinum Compounds; Precision therapeutics; Proteomics; Recurrence; Recurrent disease; Reproduction spores; Research; Research Personnel; Resistance; Resistance development; Risk; STK11 gene; Scientific Advances and Accomplishments; Specimen; Technology; Testing; Therapeutic Agents; Translating; Tumor Tissue; Validation; actionable mutation; anaplastic lymphoma kinase; base; bevacizumab; biomarker development; biomarker discovery; clinical practice; cohort; disorder control; epigenetic marker; epigenomics; improved; improved outcome; individualized medicine; inhibitor/antagonist; innovation; member; model development; mutant; new technology; new therapeutic target; next generation; novel; novel marker; novel strategies; peripheral blood; phase 3 study; prospective; research and development; response; standard of care; targeted treatment; therapy resistant; translational approach; tumor

DESCRIPTION (provided by applicant): The treatment of lung cancer has entered a new era with the identification of new molecular targets and the development of individualized treatment options. For patients with specific molecular abnormalities, targeted therapies result in robust improvements in tumor response and disease control duration. However, resistance to therapy occurs and a cure remains elusive. New approaches are needed to improve outcomes for these patients. In order to accomplish this, we need to identify novel methods to monitor patients for development of resistance with regards to specific targeted therapies. Another area of research involves developing new biomarkers to identify patients at risk for recurrence or sensitivity to specific therapeutic agents. New developments in the area of genomics, epigenetic and proteomics allow for application of these technologies in patients specimens from recent and new clinical trials conducted by the National Clinical Trials Network (NCTN). The ECOG-ACRIN group intends to establish a Translational Science Center that has a primary focus on thoracic malignancies to develop novel approaches to treat lung cancer and to develop new biomarkers that can subsequently be tested in prospective clinical trials. The main objectives of the Thoracic Malignancies Integrated Translational Science Center are: 1. To develop genomic, epigenomic and proteomics approaches to enhance biomarker discovery efforts in ongoing and planned ECOG-ACRIN studies; 2. To conduct pilot studies on existing lung cancer tumor specimens that will lead to prospective biomarker-based clinical trials; and 3. To rapidly translate the findings of the pilot projects and biomarker discovery efforts in clinical trials conducted by the ECOG-ACRIN Thoracic Committee. Salient among the proposed pilot projects include utilizing plasma DNA specimens to identify target cancer mutations, evaluation of new epigenetic markers to predict risk of recurrent disease in those with early stage lung cancer, studying the impact of LKB1 mutations in outcome for early stage lung cancer and testing novel methods to overcome resistance to targeted therapies.

描述（由申请人提供）：随着新分子靶点的确定和个体化治疗方案的开发，肺癌的治疗已经进入了一个新时代。对于具有特定分子异常的患者，靶向治疗可显著改善肿瘤缓解和疾病控制持续时间。然而，对治疗的抵抗发生并且治愈仍然难以捉摸。需要新的方法来改善这些患者的预后。为了实现这一目标，我们需要确定新的方法来监测患者对特定靶向治疗的耐药性。另一个研究领域涉及开发新的生物标志物，以识别有复发风险或对特定治疗药物敏感的患者。基因组学、表观遗传学和蛋白质组学领域的新发展允许将这些技术应用于国家临床试验网络（NCTN）最近和新进行的临床试验的患者标本。ECOG-ACRIN小组打算建立一个转化科学中心，主要关注胸部恶性肿瘤，以开发治疗肺癌的新方法，并开发新的生物标志物，随后可以在前瞻性临床试验中进行测试。胸科肿瘤综合转化科学中心的主要目标是：1。开发基因组学、表观基因组学和蛋白质组学方法，以加强正在进行和计划进行的ECOG-ACRIN研究中的生物标志物发现工作; 2.对现有的肺癌肿瘤标本进行试点研究，以开展基于生物标志物的前瞻性临床试验;以及3.在ECOG-ACRIN胸科委员会开展的临床试验中快速转化试点项目和生物标志物发现工作的结果。拟议中的试点项目包括利用血浆DNA标本来识别靶向癌症突变，评估新的表观遗传标记以预测早期肺癌患者的复发风险，研究LKB 1突变对早期肺癌结果的影响，并测试克服靶向治疗耐药性的新方法。